JP2017502013A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502013A5
JP2017502013A5 JP2016540553A JP2016540553A JP2017502013A5 JP 2017502013 A5 JP2017502013 A5 JP 2017502013A5 JP 2016540553 A JP2016540553 A JP 2016540553A JP 2016540553 A JP2016540553 A JP 2016540553A JP 2017502013 A5 JP2017502013 A5 JP 2017502013A5
Authority
JP
Japan
Prior art keywords
cas number
inhibitor
delta
cancer
intellikine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502013A (ja
JP6678584B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071747 external-priority patent/WO2015095840A1/en
Publication of JP2017502013A publication Critical patent/JP2017502013A/ja
Publication of JP2017502013A5 publication Critical patent/JP2017502013A5/ja
Application granted granted Critical
Publication of JP6678584B2 publication Critical patent/JP6678584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540553A 2013-12-20 2014-12-19 Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 Active JP6678584B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919597P 2013-12-20 2013-12-20
US61/919,597 2013-12-20
PCT/US2014/071747 WO2015095840A1 (en) 2013-12-20 2014-12-19 Cancer treatments using combinations of cdk and erk inhibitors

Publications (3)

Publication Number Publication Date
JP2017502013A JP2017502013A (ja) 2017-01-19
JP2017502013A5 true JP2017502013A5 (enExample) 2018-02-01
JP6678584B2 JP6678584B2 (ja) 2020-04-22

Family

ID=53403797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540553A Active JP6678584B2 (ja) 2013-12-20 2014-12-19 Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置

Country Status (6)

Country Link
US (5) US11013743B2 (enExample)
EP (2) EP3082423B1 (enExample)
JP (1) JP6678584B2 (enExample)
AU (1) AU2014368927B2 (enExample)
ES (1) ES3033810T3 (enExample)
WO (1) WO2015095840A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG187426A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer
JP2018526377A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
GB201605126D0 (en) 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CN115969854B (zh) * 2016-03-24 2025-12-23 科瑞华生物技术有限公司 用tg02治疗癌症
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018081204A1 (en) * 2016-10-26 2018-05-03 Li George Y DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
JP2019116429A (ja) * 2017-12-26 2019-07-18 国立大学法人名古屋大学 抗ウイルス薬
KR20200108867A (ko) 2018-01-08 2020-09-21 쥐원 쎄라퓨틱스, 인크. G1t38 우수한 투여 요법
JP7698418B2 (ja) * 2018-03-13 2025-06-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ活性化変異を有するがんを治療するための方法
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2019199883A1 (en) * 2018-04-09 2019-10-17 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
JP7507145B2 (ja) 2018-08-13 2024-06-27 ベイジン パーカンズ オンコロジー カンパニー リミテッド 癌治療のためのバイオマーカー
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
EP3923949A1 (en) * 2019-02-15 2021-12-22 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN117224679A (zh) * 2023-07-21 2023-12-15 上海交通大学医学院附属瑞金医院 选择性cdk9调节剂在制备肾上腺皮质癌药物中的应用
CN117224545A (zh) * 2023-09-26 2023-12-15 中国人民解放军陆军军医大学第二附属医院 Aminopurvalanol A在制备治疗肺腺癌的药物中的应用
WO2025111447A1 (en) * 2023-11-21 2025-05-30 Florida Atlantic University Board Of Trustees Treatment of cancer with drug combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
EA007395B3 (ru) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
HUE047130T2 (hu) * 2004-05-14 2020-04-28 Vertex Pharma Pirrol-származékok mint az erk-fehérjekinázok inhibitorai és ilyen vegyületeket tartalmazó gyógyászati készítmények
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
TW200911262A (en) * 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
SI2331547T1 (sl) * 2008-08-22 2014-11-28 Novartis Ag Pirolopirimidinske spojine kot CDK inhibitorji
TWI419974B (zh) 2008-10-27 2013-12-21 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology

Similar Documents

Publication Publication Date Title
JP2017502013A5 (enExample)
JP2017502017A5 (enExample)
JP2017502016A5 (enExample)
JP2017500320A5 (enExample)
RU2016129287A (ru) Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
Gutteridge et al. Plk1 inhibitors in cancer therapy: from laboratory to clinics
Garcia del Muro et al. A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the Spanish Group for Research on Sarcomas
Linch et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
Nonnenmacher et al. RIST: A potent new combination therapy for glioblastoma
Yesilkanal et al. New strategies for targeting kinase networks in cancer
JP2017502014A5 (enExample)
RU2717570C2 (ru) Синергистические комбинации ауристана
Bailón-Moscoso et al. Development of anticancer drugs based on the hallmarks of tumor cells
O’Sullivan Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors
EP3442529B1 (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
RU2017102319A (ru) Прерывистое введение ингибитора mdm2
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
Tsai et al. S onic H edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
EP4520398A3 (en) Treatment of prostate cancer
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
CN102264368A (zh) 极光激酶抑制剂与抗cd20抗体的组合
Lin et al. Severe neuropathic pain with concomitant administration of vincristine and posaconazole